SILEXION THERAPEUTICS CORP Net Income (Loss) Available to Common Stockholders, Basic
SILEXION THERAPEUTICS CORP (SLXN) reported Net Income (Loss) Available to Common Stockholders, Basic of $11.91 million for the 12-month period ending 2025-12-31, per its S-1/A filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-10
- SILEXION THERAPEUTICS CORP net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $4.41M, a 152.55% increase year-over-year.
- SILEXION THERAPEUTICS CORP net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $3.26M, a 72.47% decline year-over-year.
- SILEXION THERAPEUTICS CORP net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was $2.50M, a 70.04% increase year-over-year.
- SILEXION THERAPEUTICS CORP net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was $1.74M, a 26.37% increase year-over-year.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.41M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $7.67M derived: sum of 2 quarters · filed 2026-08-10 | $10.18M derived: sum of 3 quarters · filed 2026-08-10 | $11.91M S-1/A · filed 2026-08-10 |
| 2025-09-30 | $3.26M 10-Q · filed 2025-11-12 | $5.76M derived: sum of 2 quarters · filed 2025-11-12 | $7.50M 10-Q · filed 2025-11-12 | $9.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.50M 10-Q · filed 2025-08-12 | $4.24M 10-Q · filed 2025-08-12 | $5.99M derived: sum of 3 quarters · filed 2026-08-10 | $17.84M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.74M 10-Q · filed 2025-05-13 | $3.48M derived: sum of 2 quarters · filed 2026-08-10 | $15.33M derived: sum of 3 quarters · filed 2026-08-10 | $16.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | $1.75M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $13.60M derived: sum of 2 quarters · filed 2026-08-10 | $15.07M derived: sum of 3 quarters · filed 2026-08-10 | $16.44M S-1/A · filed 2026-08-10 |
| 2024-09-30 | $11.85M 10-Q · filed 2025-11-12 | $13.32M derived: sum of 2 quarters · filed 2025-11-12 | $14.70M 10-Q · filed 2025-11-12 | $16.42M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.47M 10-Q · filed 2025-08-12 | $2.85M 10-Q · filed 2025-08-12 | $4.57M derived: sum of 3 quarters · filed 2025-08-20 | $5.36M derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | $1.37M 10-Q · filed 2025-05-13 | $3.10M derived: sum of 2 quarters · filed 2025-08-20 | $3.89M derived: sum of 3 quarters · filed 2025-08-20 | $5.54M derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $1.73M derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $2.52M derived: sum of 2 quarters · filed 2025-08-20 | $4.17M derived: sum of 3 quarters · filed 2025-08-20 | $4.94M 8-K · filed 2025-08-20 |
| 2023-09-30 | $787.00K 10-Q · filed 2024-11-14 | $2.44M derived: sum of 2 quarters · filed 2024-11-14 | $3.21M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.65M 10-Q · filed 2024-08-29 | $2.43M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |